ARYx Therapeutics Inc. Commences Phase 2/3 Clinical Trial On Oral Anticoagulant Agent ATI-5923

ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced it has commenced enrollment in a Phase 2/3 clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin. The purpose of the trial, named EmbraceAC, is to evaluate whether ATI-5923 is superior to warfarin in its ability to maintain patients within a target therapeutic range of the level of anticoagulation.

More: continued here

Filed under: Blood on June 19th, 2008